Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) generates frequent news as it advances sonelokimab, an investigational Nanobody® targeting IL‑17A and IL‑17F, through late-stage clinical development in inflammatory skin and joint diseases. Company updates often center on clinical trial milestones, regulatory interactions, and financing activities that shape the outlook for its lead asset.
News items include detailed readouts from key trials such as the Phase 3 VELA program in adult hidradenitis suppurativa (HS), the adolescent VELA‑TEEN trial, the Phase 3 IZAR program in psoriatic arthritis (PsA), and Phase 2 studies like LEDA in palmoplantar pustulosis (PPP) and S‑OLARIS in axial spondyloarthritis (axSpA). Releases describe endpoints such as HiSCR75 in HS, ACR50 in PsA, PPPASI in PPP, and report on safety profiles, patient-reported outcomes and long-term follow-up analyses.
Investors following MLTX news will also see regulatory updates, including feedback from the U.S. Food and Drug Administration on the clinical evidence package for HS and guidance related to a planned Biologics License Application for sonelokimab. Financial communications, such as quarterly and annual results, equity offerings and a non-dilutive term loan facility, provide context on MoonLake’s ability to fund its clinical programs and preparations for potential commercialization.
In addition, MoonLake issues announcements about Capital Markets Days, R&D-focused webcasts and presentations at medical and investor conferences, where management discusses trial designs, baseline characteristics, interim data and anticipated milestones. This news page aggregates such releases so readers can review the evolving clinical and corporate narrative around sonelokimab and MoonLake’s broader inflammatory disease portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
